Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581059 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Ginseng for Patients on Regorafenib
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02581059 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 10 participants.
The verdict
NCT02581059, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.
Interventions
- DRUG Regorafenib
- DIETARY_SUPPLEMENT Ginseng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581059
The ClinicalTrials.gov registry entry for NCT02581059 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regorafenib is the first listed.
NCT02581059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581059 about?
NCT02581059 is a clinical study titled "Efficacy of Ginseng for Patients on Regorafenib". This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation...
What is the current status of trial NCT02581059?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-04. Estimated completion is 2018-06-22.
What interventions are being tested in trial NCT02581059?
The interventions under investigation include: Regorafenib (DRUG), Ginseng (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02581059?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.